Company Analysis
Sign in

eXoZymes Inc. (EXOZ)

Nasdaq: EXOZ · Biological Products, (No Diagnostic Substances) · Monrovia, CA · filing with the SEC since 2024
Full chart Alerts Compare
Grade5.3
◀ Past 5.7● Present 4.5▶ Future 5.6
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2023, as filed
Revenue$70,069
Net income-$2.0M
Earnings per share$-0.33
Operating cash flow-$1.2M
Cash$66,533-88.1%
Debtn/a
Shareholders’ equity-$384,319-128.0%
Shares, diluted6,250,002
Return on equity-269.6%
The recordfrom its filings
Filings in 202645
Newest filingNov 9 · FWP
Annual reportMar 30, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted2
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$10.2MCash from operations -$7.0Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

Nov 6, 2026 · SEC EDGAR · Form S-1
Listing registration
Open the filing on sec.gov
Oct 26, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 19, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 19, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 19, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 19, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 19, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 19, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton EXOZ · research, not advice